New blood test aims to predict which cancer patients will benefit from immunotherapy
NCT ID NCT07246759
First seen Jan 11, 2026 · Last updated Jun 21, 2026 · Updated 21 times
Summary
This study is developing a blood test called NeutroFlow that measures specific immune cells (neutrophils) to predict whether cancer patients will benefit from immunotherapy. Researchers will collect blood samples from 600 patients with several types of cancer before they start treatment. The goal is to create a tool that helps doctors personalize cancer care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Heidelberg University Hospital
Heidelberg, 69120, Germany
Contact Email: •••••@•••••
Contact
-
Intituto Europeo di Oncologia SRL
Milan, 20121, Italy
Contact
Contact Email: •••••@•••••
-
Virgen Macarena University Hospital - Servicio Andaluz de Salud
Seville, 41071, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this blood test could help doctors decide which patients are most likely to benefit from immunotherapy, avoiding unnecessary treatments.
What could go wrong
This is an early-stage study to develop and validate a test, not a treatment. The test may not accurately predict outcomes for all patients or cancer types.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.